ALSA Ventures

ALSA Ventures is an international life science investment firm founded in 2019 and based in London, UK. It backs early-stage biotechnology companies developing novel therapeutics, working with portfolio companies from company formation through drug development. The firm invests across the full drug-development spectrum and considers a broad range of disease areas and therapeutic modalities.

The firm's approach combines capital with company-building experience and drug development support. Opportunities are sourced on a proprietary basis, and ALSA Ventures partners with management teams to execute research and development plans, providing strategic guidance and operational expertise alongside access to a global network of industry partners. Its stated focus is on advancing breakthrough science into therapies for patients with significant unmet medical needs.

ALSA Ventures was founded by Alek Safarian and brings practical experience drawn from pharmaceutical, biotechnology and contract research organization (CRO) drug development. The firm's technical remit spans biotechnology, novel therapeutics, pharmaceutical development, CRO operations and research and development, and it operates within the life sciences, biotechnology, pharmaceuticals and drug development verticals.